A double-blind crossover study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nausea and vomiting associated with chemotherapy

Kirchner, V.; Aapro, Matti; Terrey, J. P.; Alberto, P.

doi:10.1016/s0959-8049(97)00160-3

Cited by 14 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 Besides, a separate assessment for nausea and vomiting would have given more accurate and precise estimates. The categorical reference scale for nausea and vomiting combined activities of daily living with symptoms.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, patients indicated their nausea and vomiting of the day before by a categorical, ordinal scale, 19 with 1 indicating no nausea or vomiting, 2 indicating mild nausea with no interference with daily life and no vomiting, 3 indicating severe nausea with interference with daily life but no vomiting, and 4 indicating vomiting with or without nausea. "), burden of nausea/vomiting ("To what extent have you felt bothered by nausea/vomiting or related thoughts for the past 7 days?…”

Section: Assessment Of Toxicity and Burdenmentioning

confidence: 99%

See 1 more Smart Citation

Patients' Estimation of Overall Treatment Burden: Why Not Ask the Obvious?

Bernhard¹

2002

Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Assessment Of Toxicity and Burdenmentioning

confidence: 99%

Patients' Estimation of Overall Treatment Burden: Why Not Ask the Obvious?

Bernhard¹

2002

Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…In the subsequent cycles acute vomiting was absent in 85.2%, and delayed vomiting in 63%, of patients. In comparable studies in which granisetron/dexamethasone or granisetron/prednisolone were used for prophylaxis of vomiting in patients receiving moderately emetogenic chemotherapy, complete response of acute vomiting was achieved in 73.2-95.2% of patients [12][13][14][15]. Here again, therefore, the rate of control of acute vomiting achieved using the suspension was in the upper range recorded in comparable studies.…”

Section: Discussionmentioning

confidence: 80%

Antiemetic Efficacy of an Oral Suspension of Granisetron plus Dexamethasone and Influence of Quality of Life on Risk for Nausea and Vomiting

Jordan

Grothey²,

Kegel

et al. 2005

Oncol Res Treat

View full text Add to dashboard Cite

Objectives: To assess the antiemetic efficacy of an oral suspension of granisetron/dexamethasone in patients receiving chemotherapy and to determine whether quality-of-life parameters influence the risk for postchemotherapy nausea and vomiting (PCNV). Patients and Methods: In an open monocentric study, an oral suspension containing 2 mg granisetron and 16 mg (4 mg for moderately emetogenic chemotherapy) dexamethasone was administered to 43 chemotherapy-naive patients before highly (n = 16) or moderately (n = 27) emetogenic chemotherapy and on the 3 subsequent days (2 for moderately emetogenic chemotherapy). Emetic episodes were recorded and quality of life was assessed prior to each cycle with a questionnaire based on EORTC QLQ-30. Results: In the group undergoing highly (moderately) emetogenic chemotherapy, complete control of acute vomiting was achieved in 60-72.7% (92.6-95.0% ), and complete control of delayed vomiting in 37.5-40.0% (75.0-92.2% ), of patients within the first 3 (5) cycles. The following quality-of-life parameters were significantly associated with PCNV: tiredness (RR = 1.3, p < 0.05), pain (RR = 1.5), impairment of daily life by pain (RR= 1.7), sensation of abdominal pressure and fullness (RR = 2.5), impairment of social activities (RR = 2.9). Conclusions: Once-daily oral administration of a suspension of granisetron/dexamethasone is an active prophylaxis of nausea and vomiting and compares favorably with data reported on intravenous administration. Quality-of-life parameters assessed pre-treatment could help to identify patients at high risk for nausea and vomiting so that antiemetic therapy can be tailored to individual patient risk.

show abstract

“…Polled analysis was conducted with seven AEs (dizziness, constipation, somnolence, anorexia, fatigue, insomnia, thirst) in this systematic review, and the incidence of insomnia (RR 0.12, 95% CI 0.06 to 0.26; p<0.01) was found to be significantly lower in the olanzapine groups. Insomnia is the most common AE of dexamethasone34 and olanzapine is an atypical antipsychotic agent that may cause drowsiness 35. The patients with cancer had lower insomnia when olanzapine was combined with NK-1 RA and dexamethasone.…”

Section: Discussionmentioning

confidence: 99%

Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials

et al. 2020

View full text Add to dashboard Cite

We performed a pooled analysis to evaluate the efficacy and adverse events (AEs) of olanzapine combined with dexamethasone plus 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) compared with 5-HT3 RA plus dexamethasone for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in high and moderate emetogenic chemotherapy based on randomised controlled trials (RCTs). PubMed, EMBASE, Web of Science, the Cochrane Library, China Biomedical Literature database (CBM), WanFang Database, China National Knowledge Infrastructure (CNKI), and Chinese Science and Technology Periodical Database (VIP) (from their inception to April 2019) were searched to capture relevant articles. Relative risk with 95% confidence intervals for CINV and AEs were all extracted or calculated. Eleven studies with 1107 cancer patients were involved in this review. The pooled RR of delayed CINV (RR 0.50, 95% CI 0.38 to 0.66; p<0.01) were significantly decreased in the olanzapine group. The occurrence of insomnia was also statistically decreased, as was the rate of acute CINV (RR 0.60, 95% CI 0.48 to 0.75; p<0.01). However, only the percentages of CINV III and CINV IV were significantly decreased in the acute and delayed phases. Subgroup analysis demonstrated that the efficacy was not statistically significantly different between 5 mg and 10 mg olanzapine. Olanzapine significantly decreased the occurrence of CINV III and IV and insomnia in high and moderately emetogenic chemotherapy. Compared with 10 mg per day, 5 mg oral olanzapine may be more appropriate for patients with cancer.

show abstract

A double-blind crossover study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nausea and vomiting associated with chemotherapy

Cited by 14 publications

References 27 publications

Patients' Estimation of Overall Treatment Burden: Why Not Ask the Obvious?

Patients' Estimation of Overall Treatment Burden: Why Not Ask the Obvious?

Antiemetic Efficacy of an Oral Suspension of Granisetron plus Dexamethasone and Influence of Quality of Life on Risk for Nausea and Vomiting

Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials

Contact Info

Product

Resources

About